The effects of concentrated pomegranate juice on inflammatory factors in type 2 diabetes
- Conditions
- type 2 diabetes.Non-insulin-dependent diabetes mellitus
- Registration Number
- IRCT2013091614680N1
- Lead Sponsor
- Vic chancellor for research, Ahvaz Jundishapour University of Medical Sciences
- Brief Summary
Background: The health benefits of pomegranate juice have been reported in several studies. However, limited clinical trials have examined the effects of concentrated pomegranate juice (CPJ) on inflammatory factors.<br /> Objectives: This study aimed to investigate the effects of CPJ on metabolic risk factors, including inflammatory biomarkers, in patients with type 2 diabetes mellitus.<br /> Patients and Methods: In a quasi-experiment trial, 40 type 2 diabetic patients were asked to consume 50 g of CPJ daily for 4 weeks. Anthropometric indices, dietary intake, blood pressure measurements, and fasting blood samples were conducted at baseline and 4 weeks after the intervention.<br /> Results: The intake of CPJ produced a significant increase in both total and high-density lipoprotein cholesterol (HDL-C) (4.7% and 3.9%, respectively) from baseline (P < 0.05). However, changes that were observed in serum triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose, and blood pressure were not statistically significant. Administration of CPJ caused significant reduction in serum interleukin-6 (IL-6) (P < 0.05), but tumor necrosis factor-a (TNF-a) and high-sensitivity C-reactive protein (hs-CRP) remained unchanged during the study. The mean value of serum total antioxidant capacity (TAC) was substantially increased (~ 75%) from 381.88 ± 114.4 at baseline to 1501 ± 817 after 4 weeks of CPJ consumption.<br /> Conclusions: Consumption of CPJ (50 g/day) appears to have favorable effects on some markers of subclinical inflammation, and to increase plasma concentrations of antioxidants in patients with type 2 diabetes.<br /> Keywords: Concentrated Pomegranate Juice, TNF-a, IL-6, TAC, LDL-C, HDL-C, Type 2 Diabetes, hs-CRP
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
male or female 25 to 60 years old; having type 2 diabetes at least 6 month. Exclusion criteria: pregnancy; lactation; cardiac; hepatic; respiratory and chronic renal diseases; acute or chronic inflammation; retinopathy; intake of antioxidant supplement; insulin therapy; sensitivity to concentrated pomegranate juice; change oral drug for controlling blood glucose were excluded.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Triglyceride. Timepoint: Baseline and after 4 weeks. Method of measurement: Spectrophotometry.;Total Cholesterol. Timepoint: Baseline and after 4 weeks. Method of measurement: Spectrophotometry.;HDL- Cholesterol. Timepoint: Baseline and after 4 weeks. Method of measurement: Spectrophotometry.;LDL- Cholesterol. Timepoint: Baseline and after 4 weeks. Method of measurement: Friedewald Formula.;HsCRP. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.;TNF- a. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.;IL-6. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.;Adiponectin. Timepoint: Baseline and after 4 weeks. Method of measurement: Eliza.
- Secondary Outcome Measures
Name Time Method Fasting Blood Sugar. Timepoint: baseline and after 4 weeks. Method of measurement: Spectrophotometry.;Blood Pressure. Timepoint: Baseline and after 4 weeks. Method of measurement: Sphygmomanometer.;Body Mass Index. Timepoint: baseline and after 4 weeks. Method of measurement: calculate.